StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma gross margin

Gross margin is gross profit as a percentage of revenue.

Xeris Biopharma's gross margin for the twelve months ending Jun 30, 2026 was 86.6%. For fiscal 2025 it was 85.4%, against 81.9% the year before. The highest annual figure on record is 85.4% in fiscal 2025.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202585.4%+3.6
FY2024Dec 31, 202481.9%−0.7
FY2023Dec 31, 202382.5%+3.1
FY2022Dec 31, 202279.5%+6.3
FY2021Dec 31, 202173.1%+18.8
FY2020Dec 31, 202054.4%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202686.4%+3.0
Q1 FY2026Mar 31, 202687.3%+1.8
Q4 FY2025Dec 31, 202587.2%+3.0
Q3 FY2025Sep 30, 202585.2%+10.3
Q2 FY2025Jun 30, 202583.4%−0.4
Q1 FY2025Mar 31, 202585.5%+0.2
Q4 FY2024Dec 31, 202484.2%+1.3
Q3 FY2024Sep 30, 202475.0%−8.1
Q2 FY2024Jun 30, 202483.8%+3.7
Q1 FY2024Mar 31, 202485.3%+1.3
Q4 FY2023Dec 31, 202382.9%+1.9
Q3 FY2023Sep 30, 202383.0%+0.7
Q2 FY2023Jun 30, 202380.1%−0.9
Q1 FY2023Mar 31, 202384.0%+12.4
Q4 FY2022Dec 31, 202281.0%+3.8
Q3 FY2022Sep 30, 202282.3%+11.4
Q2 FY2022Jun 30, 202281.0%+19.0
Q1 FY2022Mar 31, 202271.6%−6.1
Q4 FY2021Dec 31, 202177.2%+23.4
Q3 FY2021Sep 30, 202170.9%+0.5
Q2 FY2021Jun 30, 202162.0%–
Q1 FY2021Mar 31, 202177.7%–
Q4 FY2020Dec 31, 202053.8%–
Q3 FY2020Sep 30, 202070.4%–

More Xeris Biopharma figures

See a number that looks wrong?